Back
Top 0.7%
18.1%
#1
18.1%
#1
14.9%
Top 71%
6.6%
Top 18%
6.1%
Top 0.2%
5.1%
Top 7%
5.1%
Top 1%
3.9%
Top 2%
2.8%
Top 80%
2.0%
Top 57%
1.4%
Top 19%
1.2%
Top 12%
0.7%
Top 17%
0.7%
Top 14%
0.7%
Top 13%
0.7%
Top 3%
0.5%
Top 7%
0.5%
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)
2025-08-15
oncology
Title + abstract only
View on medRxiv
Show abstract
IntroductionCombining antibody-drug conjugates (ADCs) with radioimmunotherapy is a feasible and highly promising approach for treating HER2-positive patients, offering a potential paradigm for pan-cancer therapy. ADCs have demonstrated significant efficacy in cancers expressing human epidermal growth factor receptor 2 (HER2), independent of the tumors tissue of origin. Preclinical studies suggest that ADCs not only induce immunogenic cell death but also selectively enhance tumor radiosensitivity...
Predicted journal destinations
1
Cancers
57 training papers
2
Clinical Cancer Research
22 training papers
3
Frontiers in Oncology
34 training papers
4
PLOS ONE
1737 training papers
5
Nature Communications
483 training papers
6
BMC Cancer
21 training papers
7
eLife
262 training papers
8
British Journal of Cancer
22 training papers
9
Cancer Medicine
17 training papers
10
Scientific Reports
701 training papers
11
BMJ Open
553 training papers
12
JAMA Network Open
125 training papers
13
iScience
74 training papers
14
Nature Medicine
88 training papers
15
Heliyon
57 training papers
16
Frontiers in Immunology
140 training papers
17
Cell Reports
25 training papers
18
Journal of Clinical Investigation
50 training papers